Search results
MiNK Therapeutics secures $5.8 million for cancer therapy trials By Investing.com
Investing.com· 3 days agoThe capital is designated for advancing the clinical development of MiNK-215, an innovative cancer ...
Stock Traders Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)
ETF DAILY NEWS· 5 hours agoMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) saw some unusual options trading activity on Wednesday. Stock traders purchased 1,002 put options on the company. Maravai ...
Q1 2024 Helius Medical Technologies Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 2 days agoPoNS is different from any neuromuscular peripheral stimulation therapy, and so for the controller, we'll advocate using the gap-filling methodology based on our list < ...
Earnings call: MiNK Therapeutics advances in cancer therapy programs
Investing.com· 2 days agoMiNK Therapeutics, a pioneering company in cancer and immune-mediated disease treatment, has...
Earnings call: Ocugen reports progress in gene therapy trials and Q1 financials By Investing.com
Investing.com· 1 day agoOcugen, Inc. (NASDAQ: NASDAQ:OCGN) discussed significant advancements in its gene therapy programs...
'Like magic': This viral anti-aging wand tackles wrinkles and evens skin tone — and it's nearly 50%...
Yahoo Life Shopping· 5 days agoI’ve only used this...that little hanging piece of skin on the neck is literally getting tighter?!!...
90 swimming pools, 24-karat gold facials, and all-day champagne: Inside the Middle East’s ‘best’...
CNN via Yahoo News· 7 days agoBut there are more “accessible” ways to enjoy the resort, says Roelens: the Sky Blaze fountain, for...
Enhabit (NYSE:EHAB) Upgraded to “Market Perform” by SVB Leerink
ETF DAILY NEWS· 1 day agoThe firm currently has $8.50 target price on the stock. A number of other research analysts also recently commented on the company. UBS Group raised Enhabit from a sell rating ...
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
Zacks· 1 day agoTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Rating of “Buy” by Analysts
ETF DAILY NEWS· 3 days agoFive research analysts have rated the stock with a buy rating. A number of research analysts have issued reports on the company. Benchmark upgraded BioLife Solutions from a “neutral” rating ...
